

Summary


This study describes the development and validation of a multiplex LC-MS/MS assay to detect the protein biomarker BAG3 and its binding partner HSPB8 in heart tissue. BAG3 mutations are associated with familial dilated cardiomyopathy, making it an important biomarker for heart disease research. To overcome common challenges in multiplex protein assays, such as limited sensitivity, variable dynamic ranges, and interference from binding proteins, a hybrid workflow that analyzes a single digested tissue sample using both online antibody column anti-peptide enrichment and offline bead-based anti-peptide enrichment prior to LC-MS/MS analysis was developed. Earlier strategies using only one enrichment method showed limitations, including analyte carryover and low recovery, but combining online and offline approaches enabled reliable detection of both proteins. The final method was fully validated according to fit-for-purpose ICH M10 guidelines, demonstrating acceptable selectivity, accuracy, precision, sensitivity, and stability across a concentration range of 5 - 5,120 ng/mL in human heart tissue. Additionally, the assay was successfully translated to other species and matrices, including mouse and non-human primate tissues. Overall, this novel hybrid LC-MS/MS approach enables sensitive and selective quantification of multiple protein biomarkers from a single tissue sample with minimal processing.

Novelty

- Development and validation of a multiplexed protein biomarker in tissue using **simultaneous online and offline hybrid (anti-peptide immunoprecipitation) LC-MS/MS** approaches
- Tissue assay based on **fit-for-purpose (CoU) application of ICH M10 guidelines**
- Single sample processing** (post-digest split) into online and offline hybrid LC-MS/MS approaches
- Translation to multiple species and matrices** (mouse, NHP, human)
- Application of **custom packed anti-peptide antibody column** as well as **offline bead-based anti-peptide enrichment post digestion of a single sample** to detect a protein and its binding partner

Biological Background





Multiplex protein biomarker assays in tissue present several analytical challenges, including limited sensitivity, wide dynamic ranges, the need for multiple immunocapture reagents, and potential interference when target proteins are bound to binding partners. BAG3 is a protein associated with familial dilated cardiomyopathy when mutated and interacts with the binding protein HSPB8, making both proteins important biomarkers for studying heart disease. However, accurately quantifying both proteins simultaneously in tissue can be difficult due to these methodological limitations, highlighting the need for improved analytical approaches capable of sensitive and selective multiplex detection.



Methods

Method development included the assessment of various strategies to assay both proteins from a single sample. **Online Anti-Peptide Enrichment** - Strategies utilizing a custom packed online anti-peptide antibody column were initially investigated with variable success due to analyte carryover observed for BAG3 arising from the antibody column trap-and-elute configuration. **Offline Anti-Peptide Enrichment** - Next, a 2-plex approach utilizing offline bead-based anti-peptide enrichment was tried again with limited success due to low recovery and sensitivity for HSPB8. The reasons for the various failures are shown in this poster which led to the ultimate approach. **Multiplexed Online and Offline Anti-Peptide Enrichment** - The final method utilized a combination of online and offline immunoprecipitation approaches which successfully allowed the assay to be developed and fully validated for both proteins according to fit-for-purpose (CoU) ICH M10 guidelines.

Approximately 10 mg of human heart tissue was homogenized in RIPA buffer using the Precellys Evolution Touch Homogenizer. The supernatant of the sample was isolated and subjected to heat denaturation for 10 minutes at 95°C. The sample was then reduced and alkylated and digested with RapiZyme Trypsin for 60 minutes at 70°C. After digestion, the sample was quenched for 15 minutes at 95°C and split into 2 different immunoaffinity workflows, one utilizing an online antibody column hybrid LC-MS/MS method and one utilizing an offline hybrid (anti-peptide) LC-MS/MS bead-based enrichment with Magne™ Protein G Beads using a KingFisher Flex system. The online sample workflow was injected directly onto the multidimensional LC-MS/MS system (schematic depicted in Figure A). The offline sample workflow was injected onto a direct inject LC-MS/MS system (schematic depicted in Figure E).




Results

The method was developed and fully validated for a 5 - 5,120 ng/mL curve range in human heart tissue meeting fit-for-purpose acceptance criteria of 25%. According to the ICH M10 guidelines, selectivity, accuracy, precision, linearity, sensitivity, matrix effects, stability, dilution integrity, parallelism, and reference standards were all validated for the context of use of this protein biomarker multiplex. It should be noted that the validation data did meet the more stringent acceptance criteria of ± 20% from nominal (± 25% at LLOQ) for both proteins but we adhered to the CoU acceptance set to 25% for future sample analysis.

	Calibration Standards:										
	Cal 5	Cal 10	Cal 20	Cal 40	Cal 80	Cal 160	Cal 320	Cal 640	Cal 1280	Cal 2560	Cal 5120
Mean	5.00	10.0	20.0	40.0	80.0	160	320	640	1280	2560	5120
S.D.	0.236	0.342	0.62	0.957	1.47	3.85	4.29	10.9	16.3	69.2	108
%CV	4.6	3.6	3.2	2.4	1.8	2.4	1.3	1.7	1.2	2.6	2.4
%Bias	2.8	-3.8	-2	-2	-0.3	-0.6	0.9	2.8	2.3	2.3	-1.1
n	6	6	6	6	6	6	6	6	6	6	6

	Calibration Standards:										
	Cal 5	Cal 10	Cal 20	Cal 40	Cal 80	Cal 160	Cal 320	Cal 640	Cal 1280	Cal 2560	Cal 5120
Mean	5.05	9.95	19.7	39.3	79.7	159	321	648	1310	2600	5060
S.D.	0.16	0.239	0.378	0.935	1.14	3.06	5.34	8.07	33.5	51	113
%CV	3.2	2.4	1.9	2.4	1.4	1.9	1.7	1.2	2.6	2	3.3
%Bias	1	-0.5	-1.5	-1.8	-0.4	-0.6	0.3	1.3	2.3	1.6	-0.2
n	6	6	6	6	6	6	6	6	6	6	6



Mean Concentration	Surrogate Matrix:				
	Surr QC 5	Surr QC 15	Surr QC 200	Surr QC 2000	Surr QC 4000
5.00 ng/mL	15.0 ng/mL	200 ng/mL	2000 ng/mL	4000 ng/mL	
Found (ng/mL)	5.36	14.7	199	2050	3950
Inter-run SD	0.215	0.536	5	45.8	115
Inter-run %CV	4	3.6	2.5	2.2	2.9
Inter-run %Bias	7.2	-2	-0.5	2.5	-1
n	15	15	15	15	15

Mean Concentration	Surrogate Matrix:				
	Surr QC 5	Surr QC 15	Surr QC 200	Surr QC 2000	Surr QC 4000
5.00 ng/mL	15.0 ng/mL	200 ng/mL	2000 ng/mL	4000 ng/mL	
Found (ng/mL)	5.54	14.9	203	2050	3950
Inter-run SD	0.275	0.439	3.29	40.1	95.5
Inter-run %CV	5	2.9	1.6	2	2.4
Inter-run %Bias	10.8	-0.7	1.5	2.5	-1.3
n	15	15	15	15	15

Conclusions

This study successfully developed and validated a multiplex LC-MS/MS assay capable of quantifying the protein biomarkers BAG3 and HSPB8 in human heart tissue using a hybrid workflow that combines online antibody column anti-peptide enrichment and offline bead-based anti-peptide enrichment. The method demonstrated sensitive, selective, and reliable performance across a wide concentration range and met fit-for-purpose ICH M10 validation criteria. Additionally, the assay was qualified for use in multiple species and tissue matrices, including human, mouse, and non-human primate samples. This approach enables efficient multiplex protein biomarker analysis from a single tissue digest with minimal sample handling.